{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T12:00:20Z","timestamp":1774008020660,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"1-5","license":[{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1016\/j.jsbmb.2007.05.017","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T08:54:55Z","timestamp":1180083295000},"page":"157-161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Aromatase inhibitors and bone"],"prefix":"10.1016","volume":"106","author":[{"given":"Richard","family":"Eastell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 2","key":"10.1016\/j.jsbmb.2007.05.017_bib1","first-page":"76","article-title":"Management of bone health in postmenopausal women","volume":"64","author":"Eastell","year":"2005","journal-title":"Horm. Res."},{"key":"10.1016\/j.jsbmb.2007.05.017_bib2","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)08827-X","article-title":"Treatment of postmenopausal osteoporosis","volume":"359","author":"Delmas","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jsbmb.2007.05.017_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(06)68891-0","article-title":"Osteoporosis","volume":"367","author":"Sambrook","year":"2006","journal-title":"Lancet"},{"issue":"526","key":"10.1016\/j.jsbmb.2007.05.017_bib4","article-title":"Screening for osteoporosis in postmenopausal women: recommendations and rationale","volume":"137","author":"US Preventive Services Task Force","year":"2002","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jsbmb.2007.05.017_bib5","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1210\/jc.2004-1774","article-title":"Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study","volume":"90","author":"Reginster","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2007.05.017_bib6","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa022436","article-title":"The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis","volume":"350","author":"Meunier","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.jsbmb.2007.05.017_bib7","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJM199005033221803","article-title":"Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis","volume":"322","author":"Storm","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2007.05.017_bib8","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0002-9343(97)00278-7","article-title":"Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment","volume":"103","author":"Miller","year":"1997","journal-title":"Am. J. Med."},{"key":"10.1016\/j.jsbmb.2007.05.017_bib9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","article-title":"Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer","volume":"365","author":"Howell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jsbmb.2007.05.017_bib10","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","article-title":"A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer","volume":"350","author":"Coombes","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2007.05.017_bib11","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1056\/NEJMoa052258","article-title":"A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer","volume":"353","author":"Thurlimann","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.jsbmb.2007.05.017_bib12","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1200\/JCO.2006.08.8617","article-title":"Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98","volume":"25","author":"Coates","year":"2007","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.jsbmb.2007.05.017_bib13","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1210\/jcem.87.8.8750","article-title":"Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial","volume":"87","author":"Delmas","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2007.05.017_bib14","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.jsbmb.2007.05.017_bib15","first-page":"633","article-title":"Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial","author":"Buzdar","year":"2006","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jsbmb.2007.05.017_bib16","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jsbmb.2007.05.017_bib17","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(02)09962-2","article-title":"First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial","volume":"360","author":"Cuzick","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jsbmb.2007.05.017_bib18","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S0002-9343(99)80251-4","article-title":"The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women","volume":"99","author":"Grey","year":"1995","journal-title":"Am. J. Med."},{"key":"10.1016\/j.jsbmb.2007.05.017_bib19","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1080\/028418698430007","article-title":"Evidence that tamoxifen preserves bone density in late postmenopausal women with breast cancer","volume":"37","author":"Resch","year":"1998","journal-title":"Acta Oncol."},{"key":"10.1016\/j.jsbmb.2007.05.017_bib20","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1210\/jcem.83.4.4688","article-title":"Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients","volume":"83","author":"Marttunen","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2007.05.017_bib21","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1200\/JCO.1994.12.5.992","article-title":"Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study","author":"Kristensen","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2007.05.017_bib22","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0169-6009(08)80220-6","article-title":"Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women","volume":"22","author":"Ward","year":"1993","journal-title":"Bone Miner."},{"key":"10.1016\/j.jsbmb.2007.05.017_bib23","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJM199203263261302","article-title":"Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer","volume":"326","author":"Love","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2007.05.017_bib24","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/030089169608200114","article-title":"Effects of one-year adjuvant treatment with tamoxifen on bone mineral density in postmenopausal breast cancer women","volume":"82","author":"Barni","year":"1996","journal-title":"Tumori"},{"key":"10.1016\/j.jsbmb.2007.05.017_bib25","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF01806497","article-title":"Elemental composition of bone minerals in women with breast cancer treated with adjuvant tamoxifen","volume":"37","author":"Kalef-Ezra","year":"1996","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.jsbmb.2007.05.017_bib26","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1359\/jbmr.060508","article-title":"Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the anastrozole, tamoxifen, alone or in combination (ATAC) trial (18233230)","volume":"21","author":"Eastell","year":"2006","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jsbmb.2007.05.017_bib27","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1200\/JCO.2002.20.13.3039","article-title":"Endocrine effects of nonsteroidal aromatase inhibitors and their clinical impact","volume":"20","author":"Bajetta","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2007.05.017_bib28","first-page":"614","article-title":"Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention","volume":"11","author":"Harper-Wynne","year":"2002","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.jsbmb.2007.05.017_bib29","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1200\/JCO.2005.05.4882","article-title":"Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17","volume":"24","author":"Perez","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2007.05.017_bib30","article-title":"Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane","author":"Gonnelli","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.jsbmb.2007.05.017_bib31","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1200\/JCO.2005.07.097","article-title":"Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer","volume":"23","author":"Lonning","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.jsbmb.2007.05.017_bib32","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1200\/JCO.2005.05.3744","article-title":"Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer","volume":"25","author":"Brufsky","year":"2007","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.jsbmb.2007.05.017_bib33","first-page":"S27","article-title":"Risk factors for fracture: 5-year results of the \u2019Arimadex\u2019 (anastrozole), tamoxifen, alone or in combination (ATAC)","volume":"78","author":"Eastell","year":"2006","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.jsbmb.2007.05.017_bib34","first-page":"S25","article-title":"Effect of anastrozole on bone mineral density: 5-year results of the \u2019Arimadex\u2019 (anastrozole), tamoxifen, alone or in combination (ATAC) study","volume":"78","author":"Eastell","year":"2006","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.jsbmb.2007.05.017_bib35","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.jsbmb.2007.05.017_bib36","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jsbmb.2007.05.017_bib37","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.jsbmb.2007.05.017_bib38","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1359\/JBMR.050313","article-title":"Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study","volume":"8","author":"Miller","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jsbmb.2007.05.017_bib39","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"8","author":"Chesnut","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jsbmb.2007.05.017_bib40","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jsbmb.2007.05.017_bib41","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2007.05.017_bib42","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0002-9343(00)00490-3","article-title":"A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study","volume":"109","author":"Chesnut","year":"2000","journal-title":"Am. J. Med."}],"container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076007001203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076007001203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:55:04Z","timestamp":1760734504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960076007001203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":42,"journal-issue":{"issue":"1-5","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["S0960076007001203"],"URL":"https:\/\/doi.org\/10.1016\/j.jsbmb.2007.05.017","relation":{},"ISSN":["0960-0760"],"issn-type":[{"value":"0960-0760","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aromatase inhibitors and bone","name":"articletitle","label":"Article Title"},{"value":"The Journal of Steroid Biochemistry and Molecular Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsbmb.2007.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}